Avonex

Plegridy approval underlines Biogen Idec's dominance in MS

This includes Avonex, which is one of Biogen's leading products, pulling in sales of around $3bn last year. ... The new drug is dosed once every two weeks - compared to once a week for Avonex - and is the only pegylated version of interferon beta on the

CHMP backs European approval for six new medicines

Avonex (interferon beta-1a) on track for approval in mid-2014. ... Plegridy requires less frequent injections than Avonex and is administered subcutaneously rather than intramuscularly, so should be less painful for patients.

Sales down at Merck Serono on Rebif pressure

which was overshadowed by exchange rate factors and the loss of 30m-worth of royalty income on sales of Biogen Idec's MS drug Avonex (interferon beta-1a) in the quarter.

Rocketing Tecfidera sales give Biogen Idec stellar Q3 results

Avonex (interferon beta-1a) slipped slightly to $733m in the third quarter but gained market share in the injectable MS therapy segment. ... There was mixed news for Biogen Idec's R&D pipeline, however. A pegylated version of Avonex called Plegridy could

Biogen Idec's long-acting beta interferon moves ahead in MS

The benefits of Plegridy are that it will require less frequent injections than Avonex and will be administered subcutaneously rather than intramuscularly, so should be less painful. ... The new product is given once every two or four weeks, while Avonex

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]